The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Valium was the most versatile of the minor tranquilizers. Later came the widespread adoption of major tranquilizers such as chlorpromazine and the drug reserpine. In 1970, sales began to decline for Valium and Librium, but sales of new and improved tranquilizers, such as Xanax, introduced in 1981 for the newly created diagnosis of panic disorder, soared. Mevacor (lovastatin) is the first and most influential statin in the American market. The 1991 launch of Pravachol (pravastatin), the second available in the United States, and the release of Zocor (simvastatin) made Mevacor no longer the only statin on the market. In 1998, Viagra was released as a treatment for erectile dysfunction.
g(l) and g(s) are g-factors of the nucleons. Since the proton and neutron have different values for g(l) and g(s), one must separate their contributions. Each gets half of the deuterium orbital angular momentum
Selenium disulfide, also known as selenium sulfide, is a chemical compound and medication used to treat seborrheic dermatitis, dandruff, and pityriasis versicolor. It is applied to the affected area as a lotion or shampoo. Symptoms frequently return if treatment is stopped. Side effects may include hair discoloration, skin irritation, and risk of systemic absorption and toxicity, among others. Use is not recommended in children less than 2–5 years old. Use in pregnancy or breastfeeding has not been studied. It consists of a mixture of inorganic covalent compounds having an approximate empirical formulas of SeS2. Selenium disulfide acts as a keratolytic and antifungal agent. Selenium disulfide was approved for medical use in the United States at least as early as 1951. It is on the World Health Organization's List of Essential Medicines. Selenium disulfide is available as a generic medication and over the counter.
=== Awards and honours === Scrutton was awarded the Colworth Medal in 1999 from the Biochemical Society; the Enzyme Chemistry Award (Charmian Medal) from the Royal Society of Chemistry in 2002; the Rita and John Cornforth Award from the Royal Society of Chemistry in 2009; the Interdisciplinary Prize from the Royal Society of Chemistry in 2019. Scrutton was elected a Fellow of the Royal Society (FRS) in 2020; Fellow of the Royal Society of Chemistry (FRSC) in 1996; a Fellow of the Royal Society of Biology (FRSB) in 2009; a Member of the Lister Institute in 2004. He is recipient of a number of academic awards including: Sambrooke Exhibition Prize (King's College London, University of London, 1983); William Robson Prize (King's College London, University of London, 1985); Benefactors' Scholarship (St John's College, University of Cambridge, 1985); Henry Humphreys Research Prize / Research Fellowship (St John's College, University of Cambridge, 1989).
=== Notable cases === Dan Christensen, painter of abstract art. Died due to heart failure caused by polymyositis. Robert Erickson, American composer and teacher who was a leading modernist exponent of "12-tone" composition. Died from the effects of polymyositis. Ana Estrada, the first person in Peru to die by euthanasia on 21 April 2024, at the age of 47. David Lean, film director. Eric Samuelsen, playwright. Victor Manuel Resendiz Ruiz, wrestler. Cardinal John Wright Rosita Velazquez, Puerto Rican actress and singer.
Sources: en.wikipedia.org
== Taxonomy == Tricholoma equestre was known to Carl Linnaeus, who officially described it in Volume Two of his Species Plantarum in 1753, giving it the name Agaricus equestris, predating a description of Agaricus flavovirens by Persoon in 1793. Thus this specific name meaning "of or pertaining to horses" in Latin takes precedence over Tricholoma flavovirens, the other scientific name by which this mushroom has been known. It was placed in the genus Tricholoma by German Paul Kummer in his 1871 work Der Führer in die Pilzkunde. The generic name derives from the Greek trichos/τριχος 'hair' and loma/λωμα 'hem', 'fringe' or 'border'. Common names include the man-on-horseback, yellow knight, and saddle-shaped tricholoma.
== Occurrence == Dimethyl trisulfide has been found in volatiles emitted from cooked onion, leek and other Allium species, from broccoli and cabbage, as well as from Limburger cheese, and is involved in the unpalatable aroma of aged beer and stale Japanese sake. It is a product of bacterial decomposition, including the early stages of human decomposition, and is a major attractant for blowflies looking for hosts. Dimethyl trisulfide along with dimethyl sulfide and dimethyl disulfide have been confirmed as volatile compounds given off by the fly-attracting plant known as dead-horse arum (Helicodiceros muscivorus). These flies are attracted to the odor of fetid meat and help pollinate this plant. DMTS contributes to the foul odor given off by the fungus Phallus impudicus, also known as the common stinkhorn. DMTS causes the characteristic malodorous smell of a fungating lesion, e.g., from cancer wounds, and contributes to the odor of human feces. DMTS can be synthesized by the reaction of methanethiol with hydrogen sulfide (in the presence of copper (II)) and with sulfur dichloride, among other methods:
=== Pathways === Until recently, necrosis was thought to be an unregulated process. However, there are two broad pathways in which necrosis may occur in an organism. The first of these two pathways initially involves oncosis, where swelling of the cells occurs. Affected cells then proceed to blebbing, and this is followed by pyknosis, in which nuclear shrinkage transpires. In the final step of this pathway cell nuclei are dissolved into the cytoplasm, which is referred to as karyolysis. The second pathway is a secondary form of necrosis that is shown to occur after apoptosis and budding. In these cellular changes of necrosis, the nucleus breaks into fragments (known as karyorrhexis).
In the United States between 2020 and 2022, the number of e-cigarettes sold had climbed to 22.7 million units. Elf Bar/EBDESIGN, Vuse, JUUL, NJOY and Breeze Smoke were recognized as the five most popular brands as of December 2022. The surge was driven by non-tobacco flavors such as menthol (for prefilled cartridges) and fruit and candy (for disposables), according to the CDC's health economist Fatma Romeh Ali. In the UK, where most vaping uses refillable sets and e-liquid, there is now support from the National Health Service, and other medical bodies now embrace the use of e-cigarettes as a viable way to quit smoking. This has contributed to record numbers of people vaping, with an estimated 3.6 million in 2021. Nationally, about 7% of children and teenagers (aged 11–17) currently vape, which equates to roughly 400,000 children in Great Britain. Additionally, around 20% of young people have tried vaping at least once. Many vape brands are popular such as Lost mary Bm600 disposables (one use products) and The R and M Tornado 9000. "In 2025, reports highlighted the rise of illegal 'mega vapes' being sold to minors."
Sources: en.wikipedia.org
The oldest known constructed roadways are the stone-paved streets of the city-state of Ur, dating to c. 4,000 BCE, and timber roads leading through the swamps of Glastonbury, England, dating to around the same period. The first long-distance road, which came into use around 3,500 BCE, spanned 2,400 km from the Persian Gulf to the Mediterranean Sea, but was not paved and was only partially maintained. Around 2,000 BCE, the Minoans on the Greek island of Crete built a 50 km road leading from the palace of Gortyn on the south side of the island, through the mountains, to the Palace of Knossos on the north side of the island. Unlike the earlier road, the Minoan road was completely paved. Ancient Minoan private homes had running water. A bathtub virtually identical to modern ones was unearthed at the Palace of Knossos. Several Minoan private homes also had toilets, which could be flushed by pouring water down the drain. The ancient Romans had many public flush toilets, which emptied into an extensive sewage system. The primary sewer in Rome was the Cloaca Maxima; construction began on it in the sixth century BCE, and it is still in use today. The ancient Romans also had a complex system of aqueducts, which were used to transport water across long distances. The first Roman aqueduct was built in 312 BCE. The eleventh and final ancient Roman aqueduct was built in 226 CE. Put together, the Roman aqueducts extended over 450 km, but less than 70 km of this was above ground and supported by arches.
There are also a few thousand Druze immigrants from Lebanon in the United States of America, who have converted to Christianity. In the period of Egyptian rule in the Levant in the 1830s, many Druze converted to Christianity to avoid enlistment into the Egyptian army. The baptism of children in accordance with Christian custom was usual in large, well-known Lebanese Druze families, according to historian Aharon Layish there is also explicit evidence of Druzes in Lebanon under the Ottoman rule were posing Christians for practical reasons. The early Druze migrants from Levant to Venezuela tended to mix well with the local population, and some Druze converted to Catholicism. By one estimate made by Elisabe Granli from University of Oslo, around 1,920 Syrian Druze converted to Christianity; according to the same study, Christians with a Druze background (Druze converts to Christianity) still regard themselves as Druze, and claim that there is no contradiction between being Druze and being Christian. According to the Druze religious courts, between 1952 and 2009, around 10% of Israeli Druze who left the Druze faith converted to Christianity. According to Open Doors, there is a small but growing community of Druze converts to Christianity in Syria and Lebanon, with most converting to Evangelical Protestantism. These converts have established churches specifically for Christians of Druze background, primarily comprising women, girls, and young men who have abandoned the Druze religion they were raised in.
== Research == There is currently a great deal of research being conducted on hemostasis. The most current research is based on genetic factors of hemostasis and how it can be altered to reduce the cause of genetic disorders that alter the natural process hemostasis. Von Willebrand disease is associated with a defect in the ability of the body to create the platelet plug and the fibrin mesh that ultimately stops the bleeding. New research is concluding that the von Willebrand disease is much more common in adolescence. This disease negatively hinders the natural process of Hemostasis causing excessive bleeding to be a concern in patients with this disease. There are complex treatments that can be done including a combination of therapies, estrogen-progesterone preparations, desmopressin, and Von Willebrand factor concentrates. Current research is trying to find better ways to deal with this disease; however, much more research is needed in order to find out the effectiveness of the current treatments and if there are more operative ways to treat this disease.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.